(AOF) – Abionyx Pharma announces new positive results in ophthalmology in the first class of biomedicines from CER-001 for the treatment of ocular pathologies. This biotech specialist in innovative therapies based on the only natural recombinant apoA-I in the world adds that the anti-inflammatory and/or increased reverse lipid transport properties of CER-001, and these new preclinical results in uveitis ” pave the way for the start of clinical studies testing apoA-I in patients with other severe inflammatory pathologies.”
Jérôme Martinez has been appointed Senior Advisor to Abionyx Pharma for the development of CER-001 in ophthalomy. He has more than 30 years of experience in the management of companies in the pharmaceutical and biotechnology sector in France and internationally, having been President of operations in France for the Japanese pharmaceutical laboratory Santen specializing in ophthalmology and rheumatology.
AOF – LEARN MORE
Learn more about the Pharmacy sector
Oncology, priority of pharmaceutical giants
Sanofi’s stock market disappointment recorded at the end of October 2023 underlines the new direction for the group, which has now set oncology as its number 1 priority. Efforts in this segment, where therapies are advancing the fastest, notably involve investments in R&D which weigh on profitability. Sanofi therefore announced a drop in its earnings per share in 2024 and the abandonment of its objective of an operating margin of 32% in 2025. Merck has just unveiled a new alliance. It will pay up to $22 billion to the Japanese group Daiichi Sankyo as part of a partnership on experimental cancer treatments. While some experts estimate that the United States represents nearly half of global oncology spending (drugs and treatments), or $196 billion in 2022, Chinese spending in this area has more than doubled in five years, going from 5 to 11.8 billion dollars.